Physician profile
Peter Lu
NPI 1689674046
$4,674.09
in general payments reported to CMS, 2019-2025
11 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $786 · 2021: $900 · 2022: $886 · 2023: $379 · 2024: $228 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $2,077.04 | 2019-2023 | Menopur |
| Organon LLC | $881.00 | 2021-2025 | Ganirelix Acetate, Follistim Aq, Pregnyl |
| Merck Sharp & Dohme LLC | $789.45 | 2019-2021 | |
| Emd Serono, INC. | $274.08 | 2019-2024 | |
| Galen US INC | $188.77 | 2019-2021 | |
| Aspira Women'S Health INC | $161.77 | 2022 | |
| Myriad Women'S Health, INC. | $144.14 | 2023 | Genesight |
| Abbvie INC. | $91.79 | 2019-2022 | |
| Virtus Pharmaceuticals LLC | $34.75 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $15.69 | 2022 | |
| Millicent US INC | $15.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.